You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
McKee's Pathology of the Skin is the most complete, in-depth resource on dermatopathology, covering etiology, pathogenesis, disease mechanisms, and recent genetic, molecular, and basic science data. Drs. J. Eduardo Calonje, Thomas Brenn, Alexander Lazar, and Phillip McKee present new illustrations, updated chapters, and coverage of new entities such as lymphomas, cutaneous tissue tumors, diseases of the nail, and more in this extensively revised fourth edition. This new edition is an absolute must for practicing dermatopathologists and general pathologists who sign out skin biopsies. It has over 5,000 images and new chapters on the pathology of HIV/AIDS, conjunctival tumors, sentinel lymph n...
Magical mind control Lina accidentally gave a batch of her fudge an extra wallop. Anyone who eats it becomes suggestible. Very suggestible. Is it mind control? First a nun robs a liquor store, then a kindergarten teacher punches a pedestrian. The International Criminal Witch Police are certain Lina’s fudge is to blame. When a third crime demonstrates an escalating pattern of violence, Lina is terrified a fourth offense will end with murder. Does the mastermind behind the crimes have a twisted sense of humor, or is there a more sinister connection behind the crimes? Join Lina as she cleans up the last (she hopes!) of her cursed candy messes and tracks down a potential killer. Fatal Fudge is a magical witch culinary cozy with a touch of romance, the third of three books in the Cursed Candy Mysteries series! Cursed Candy Mysteries includes: Cutthroat Cupcakes Twisted Treats Fatal Fudge
Pathology and Genetics of Skin Tumours is the latest volume in the new WHO series on histological and genetic typing of human tumours. This publication, offers an authorative and concise reference book, providing an international standard for dermatologists, pathologists and oncologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome. Diagnostic criteria, pathological features, and associated genetic alterations are described in strictly disease-oriented manner. Sections on all WHO-recognized neoplasms and their variants include ICD-O codes, incidence, age and sex distribution, location, clinical signs and symptoms, pathology, genetics, and predictive factors. The book, prepared by more than 150 authors from 20 countries, contains 648 colour photographs, clinical images and charts, amd more than 2600 references. This volume covers keratinocytic, melanocytic, appendageal, haematopoietic, soft tissue and neural tumours, as well as inherited tumour syndromes. Each entity is extensively discussed with information on clinicopathological, epidemiological, immunophenotypic and genetic aspects of these diseases.
Textbook of Pathology - E-Book
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.
Since the first edition of this book in 2012, the field of molecular pathology has expanded exponentially. The advent of complete cancer genome sequencing, new diagnostic molecular tests, and biomarkers for targeted therapy and immunotherapy have demonstrated the importance of molecular tools both in patient care and in the practice of pathology. Furthermore, the development of many new molecular technologies has revolutionized the practice of modern pathology. The rapid growth of this field has led to an expansion of knowledge of molecular processes and many more clinical applications in our daily practice of surgical pathology. Thus, this updated second edition of Molecular Surgical Pathol...
Melanoma is one of the most types of cancer. When melanoma is detected at an early stage, treatment is highly successful, but outcomes can be poor when the disease is advanced. There has been significant progress in our understanding of the molecular biology, genetics, and immunology of melanoma over the past decade. This has been accompanied by rapid advances in therapeutic strategies for patients with melanoma. This book provides the clinician and the researcher with a broad understanding of the molecular and cellular pathogenesis of melanoma, explores the clinical characteristics and criteria for clinical and pathological staging of the disease, and provides an overview of current and evolving treatment strategies in the adjuvant, metastatic, and preventive settings. The treatment of special populations and rare variants of melanoma that often present particular clinical challenges is also covered. Authored by international experts in melanoma biology and clinical management, this volume concisely explains how to diagnose, treat, and prevent melanoma while reviewing advances in basic science and providing an overview of innovative approaches still under development.
Textbook of Pathology - E-Book
This text serves as a very useful clinical guide and realistic approach to the clinical management of melanoma. Primary care physicians, specialists from varying areas of medical practice and numerous other healthcare providers will find this text to be quite useful as a standard daily reference and use in the office setting. It provides a clear and concise source of information in order to make real-life, evidence-based decisions for all aspects of management for cutaneous melanoma. This book also provides the latest breakthroughs in melanoma research, ranging from recent discoveries in genomics and epigenetics, to newly identified genes that have been selectively targeted for the development of a personalized approach to treatment. All chapters are written by specialists and true experts within their respective fields, incorporating the latest scientific, clinical and evidence-based medicine for melanoma (and non-melanoma skin cancers). This up-to-date information can be easily applied and translated to the clinical setting for the melanoma patient.
Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas – over-exposure to ultraviolet light – is well known, effective treatment has remained challenging. The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies. This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers.